These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 9764793)

  • 21. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound.
    Scriba TJ; Zhang HT; Brown HL; Oxenius A; Tamm N; Fidler S; Fox J; Weber JN; Klenerman P; Day CL; Lucas M; Phillips RE
    J Clin Invest; 2005 Feb; 115(2):443-50. PubMed ID: 15668739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cd4+ T cells programmed to traffic to lymph nodes account for increases in numbers of cd4+ T cells up to 1 year after the initiation of highly active antiretroviral therapy for human immunodeficiency virus type 1 infection.
    Hengel RL; Jones BM; Kennedy MS; Hubbard MR; McDougal JS
    J Infect Dis; 2001 Jul; 184(1):93-7. PubMed ID: 11398115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.
    Binley JM; Schiller DS; Ortiz GM; Hurley A; Nixon DF; Markowitz MM; Moore JP
    J Infect Dis; 2000 Apr; 181(4):1249-63. PubMed ID: 10762561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions.
    Hawley-Foss N; Mbisa G; Lum JJ; Pilon AA; Angel JB; Garber G; Badley AD
    Clin Infect Dis; 2001 Aug; 33(3):344-8. PubMed ID: 11438900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of HIV despite the discontinuation of antiretroviral therapy.
    Lisziewicz J; Rosenberg E; Lieberman J; Jessen H; Lopalco L; Siliciano R; Walker B; Lori F
    N Engl J Med; 1999 May; 340(21):1683-4. PubMed ID: 10348681
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antiretroviral treatment: when to start and with what?].
    Soriano V; Jiménez-Nácher VS
    Med Clin (Barc); 1998 Jul; 111(4):137-41. PubMed ID: 9717146
    [No Abstract]   [Full Text] [Related]  

  • 31. [Not Available].
    Dialer I; Seybold U; Bogner J
    MMW Fortschr Med; 2015 Jun; 157 Suppl 2():33-5. PubMed ID: 26048118
    [No Abstract]   [Full Text] [Related]  

  • 32. Down or out in blood and lymph?
    Wain-Hobson S
    Nature; 1997 May; 387(6629):123-4. PubMed ID: 9144275
    [No Abstract]   [Full Text] [Related]  

  • 33. How does HIV overcome the body's T cell bodyguards?
    Balter M
    Science; 1997 Nov; 278(5342):1399-400. PubMed ID: 9411761
    [No Abstract]   [Full Text] [Related]  

  • 34. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy.
    Chaisson RE; Keruly JC; Moore RD
    JAMA; 2000 Dec; 284(24):3128-9. PubMed ID: 11135775
    [No Abstract]   [Full Text] [Related]  

  • 35. Can immune systems be trained to fight HIV?
    Balter M
    Science; 1999 Nov; 286(5444):1470-11. PubMed ID: 10610544
    [No Abstract]   [Full Text] [Related]  

  • 36. Can HIV be cured?
    Stevenson M
    Sci Am; 2008 Nov; 299(5):78-83. PubMed ID: 18998350
    [No Abstract]   [Full Text] [Related]  

  • 37. Analysis of alveolar and peripheral CD45RO+ T-lymphocytes in sarcoidosis.
    Perari MG; Forteleoni GM; Rollo M; Perrella A; Collodoro A; Rottoli P; Vagliasindi M
    Sarcoidosis; 1993 Sep; 10(2):163-4. PubMed ID: 8140318
    [No Abstract]   [Full Text] [Related]  

  • 38. Recent developments in research of HIV infection--a "state of art" (a review).
    Füst G
    Acta Microbiol Immunol Hung; 1994; 41(1):5-21. PubMed ID: 7921851
    [No Abstract]   [Full Text] [Related]  

  • 39. T-helper cell responses among HIV-infected children in Soweto, South Africa.
    Meyers TM; Kuhn L; Meddows-Taylor S; Simmank K; Sherman GG; Tiemessen CT
    Ann N Y Acad Sci; 2000 Nov; 918():373-6. PubMed ID: 11131729
    [No Abstract]   [Full Text] [Related]  

  • 40. Nutrition. Two German studies find NAC supplements helpful.
    TreatmentUpdate; 2001; 12(9):3-5. PubMed ID: 12132446
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.